

2cureX AB accelerates reintegration of operating business into the listed company

2cureX AB (publ) (“2cureX” or the “Company”) today announces that it will submit extensive documentation to Nasdaq Stockholm demonstrating the Company’s ongoing commercial activities, operational execution and strategic development. At the same time, the Boards of 2cureX AB and 2cureX A/S have decided to accelerate the planned reintegration of the operating business into the listed company.

The private 2cureX A/S will re-enter the listed 2cureX AB.

During the spring of 2024, the Board of 2cureX AB initiated a complete technical transformation of the IndiTreat platform, moving from centralised testing within the Company’s own laboratories to decentralised testing directly at hospitals. As financing this transformation proved challenging within the listed environment, a private investor consortium acquired 2cureX A/S to complete the development programme.

With private funding, 2cureX A/S has now completed the technical turnaround of the IndiTreat platform, including the development of the decentralised workflow, associated medical device and the required regulatory development. The Company expects IndiTreat installations to commence during the second half of 2026 at hospitals in Copenhagen (Denmark), Lund (Sweden), Hamburg (Germany) and Madrid (Spain).

The reintegration of 2cureX A/S into the listed company had originally been planned for the autumn of 2026. Following Nasdaq Stockholm’s ongoing review of the Company’s continuing listing requirements, both Boards have agreed to accelerate this process and are working towards completing the reintegration during August 2026.

In connection with this review, Nasdaq Stockholm has informed the Company that, based on the information currently available to the Exchange, its preliminary assessment is that the Company does not currently fulfil the continuing listing requirements relating to ongoing business operations under the Nasdaq First North Growth Market Rulebook.

Nasdaq has requested that the Company provide additional supporting information by 14 August 2026. The Company will submit extensive documentation evidencing its ongoing business operations, customer activities, commercial execution and strategic initiatives, and will continue to engage constructively with Nasdaq throughout the review process.

The Company will provide further updates regarding the reintegration of 2cureX A/S and the Nasdaq review as soon as appropriate.